Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Jaguar Licenses Oral Mucositis Product for U.S. Market in Cancer Care
Details : Gelclair will be commercialized by Jaguar Health in the U.S. to alleviate pain from oral lesions, including mucositis and stomatitis.
Product Name : Gelclair
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Maltodextrin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Jaguar Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
